The effect of endostatin evaluated in an experimental animal model of collagen‐induced arthritis

References

• Koch A. E. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62((Suppl 2))ii60–7
   PubMed Web of Science ®Google Scholar
• Paleolog E. M., Miotla J. M. Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis 1998; 2: 295–307
   PubMedGoogle Scholar
• Brenchley P. E. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000; 121: 426–9
   PubMed Web of Science ®Google Scholar
• Walsh D. A., Haywood L. Angiogenesis: a therapeutic target in arthritis. Curr Opin Invest Drugs 2001; 2: 1054–63
   PubMedGoogle Scholar
• O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–85
   PubMed Web of Science ®Google Scholar
• Pufe T., Petersen W. J., Miosge N., Goldring M. B., Mentlein R., Varoga D. J., et al. Endostatin/collagen XVIII – an inhibitor of angiogenesis – is expressed in cartilage and fibrocartilage. Matrix Biol 2004; 23: 267–76
   PubMed Web of Science ®Google Scholar
• Matsuno H., Yudoh K., Uzuki M., Nakazawa F., Sawai T., Yamaguchi N., et al. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol 2002; 29: 890–5
   PubMed Web of Science ®Google Scholar
• Yin G., Liu W., An P., Li P., Ding I., Planelles V., et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002; 5: 547–54
   PubMed Web of Science ®Google Scholar
• Kurosaka D., Yoshida K., Yasuda J., Yokoyama T., Kingetsu I., Yamaguchi N., et al. Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis 2003; 62: 677–9
   PubMed Web of Science ®Google Scholar
• Yue L., Wang H., Liu L. H., Shen Y. X., Wei W. Anti‐adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol Sin 2004; 25: 1182–5
   PubMed Web of Science ®Google Scholar
• Kisker O., Becker C. M., Prox D., Fannon M., D'Amato R., Flynn E., et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669–74
   PubMed Web of Science ®Google Scholar
• Yamaguchi N., Anand‐Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., et al. Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414–23
   PubMed Web of Science ®Google Scholar
• Terato K., Hasty K. A., Reife R. A., Cremer M. A., Kang A. H., Stuart J. M. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992; 148: 2103–8
   PubMed Web of Science ®Google Scholar
• Kagari T., Doi H., Shimozato T. The importance of IL‐1 beta and TNF‐alpha, and the noninvolvement of IL‐6, in the development of monoclonal antibody‐induced arthritis. J Immunol 2002; 169: 1459–66
   PubMed Web of Science ®Google Scholar
• Miotla J., Maciewicz R., Kendrew J., Feldmann M., Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen‐induced arthritis. Lab Invest 2000; 80: 1195–205
   PubMed Web of Science ®Google Scholar
• Luttun A., Tjwa M., Moons L., Wu Y., Angelillo‐Scherrer A., Liao F., et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti‐Flt1. Nature Med 2002; 8: 831–40
   PubMed Web of Science ®Google Scholar
• Wauke K., Nagashima M., Ishikawa T., Asano G., Yoshino S. Expression and localization of vascular endothelial growth factor‐C in rheumatoid arthritis synovial tissue. J Rheumatol 2002; 29: 34–8
   PubMedGoogle Scholar
• Shahrara S., Volin M. V., Connors M. A., Haines G. K., Koch A. E. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002; 4: 201–8
   PubMedGoogle Scholar
• Debusk L. M., Chen Y., Nishishita T., Chen J., Thomas J. W., Lin P. C. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factorα‐induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003; 48: 2461–71
   PubMed Web of Science ®Google Scholar
• Morris R., Winyard P. G., Brass L. F., Blake D. R., Morris C. J. Thrombin receptor expression in rheumatoid and osteoarthritic synovial tissue. Ann Rheum Dis 1996; 55: 841–3
   PubMedGoogle Scholar
• Ferrell W. R., Lockhart J. C., Kelso E. B., Dunning L., Plevin R., Meek S. E., et al. Essential role for proteinase‐activated receptor‐2 in arthritis. J Clin Invest 2003; 111: 35–41
   PubMed Web of Science ®Google Scholar
• Szekanecz Z., Haines G. K., Harlow L. A., Shah M. R., Fong T. W., Fu R., et al. Increased synovial expression of the adhesion molecules CD66a, CD66b, and CD31 in rheumatoid and osteoarthritis. Clin Immunol Immunopathol 1995; 76: 180–6
   PubMedGoogle Scholar
• Volin M. V., Szekanecz Z., Harloran M. M., Woods J. M., Magua J., Damergis J. A Jr., et al. PECAM‐1 and leukosialin (CD43) expression correlate with heightened inflammation in rat adjuvant‐induced arthritis. Exp Mol Pathol 1999; 66: 211–19
   PubMedGoogle Scholar
• Szekanecz Z., Haines G. K., Harlow L. A., Shah M. R., Fong T. W., Fu R., et al. Increased synovial expression of transforming growth factor (TGF)‐beta receptor endoglin and TGF‐beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76: 187–94
   PubMedGoogle Scholar
• Lu J., Kasama T., Kobayashi K., Yoda Y., Shiozawa F., Hanyuda M., et al. Vascular endothelial growth factor expression and regulation of murine collagen‐induced arthritis. J Immunol 2000; 164: 5922–7
   PubMed Web of Science ®Google Scholar
• Fava R. A., Olsen N. J., Spencer‐Green G., Yeo K. T., Berse B., Jackman R. W., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341–6
   PubMed Web of Science ®Google Scholar
• Mould A. W., Tonks I. D., Cahill M. M., Pettit A. R., Thomas R., Hayward N. K., et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen‐induced and collagen‐induced models of arthritis. Arthritis Rheum 2003; 48: 2660–9
   PubMed Web of Science ®Google Scholar
• Pufe T., Petersen W., Tillmann B., Mentlein R. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1482–5
   PubMedGoogle Scholar
• Cinelli M., Guiducci S., Del Rosso A., Pignone A., Del Rosso M., Fibbi G., et al. Piascledine modulates the production of VEGF and TIMP‐1 and reduces the invasiveness of rheumatoid arthritis synoviocytes. Scand J Rheumatol 2006; 35: 346–50
   PubMed Web of Science ®Google Scholar
• Abdollahi A., Hahnfeldt P., Maercker C., Grone H. J., Debus J., Ansorge W., et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649–63
   PubMed Web of Science ®Google Scholar
• Vergunst C. E., van de Sande M. G., Lebre M. C., Tak P. P. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005; 34: 415–25
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenesis in cancer therapy – endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594–607
   PubMed Web of Science ®Google Scholar